What is Horizon Two?

Horizon Two is a unique clinical trial (known as an adaptive platform trial) sponsored by the Multiple Myeloma Research Foundation (MMRF).

The study is designed specifically for patients with high-risk, newly diagnosed multiple myeloma, a group of patients who often do not respond as well to standard treatments and may see their disease return more quickly.

Unlike traditional clinical trials that test only one treatment at a time, Horizon Two is designed to evaluate multiple treatment approaches within the same study. As new therapies become available, they can be added to the trial as new groups (also called “arms”), allowing the study to continue evolving as research advances.

This flexible design helps researchers:

• Study promising treatments more quickly
• Learn which treatment combinations work best
• Improve options for patients with high-risk multiple myeloma
• Bring new research findings to patients faster

What treatment is Horizon Two testing?

The current study arms are evaluating whether newer immunotherapy-based treatment combinations may improve outcomes for patients with high-risk, newly diagnosed multiple myeloma.

The trial is studying treatment approaches that include:

• Bispecific antibody therapy
• Combination drug regimens
• Stem cell transplant
• Maintenance therapy

Researchers will evaluate:

• How well treatments control multiple myeloma
• Which treatment combinations are most effective
• Side effects and safety
• Whether patients can safely stop treatment altogether after a sustained period of negative minimal residual disease (MRD).

Additional treatment groups may be added to Horizon Two over time as new therapies become available.

What is a Bispecific Antibody?

Some treatment groups in Horizon Two include medicines called bispecific antibodies, such as Lynozyfic^® (linvoseltamab). 

Bispecific antibodies are designed to help the immune system recognize and attack multiple myeloma cells. 

These therapies have already shown encouraging results in patients whose myeloma returned after prior treatment. Horizon Two is studying whether these approaches may also help patients earlier in their treatment journey. 

Why focus on High-Risk Multiple Myeloma?

While many patients with multiple myeloma have benefited from major advances in treatment over the last two decades, patients with high-risk disease still face significant challenges.

High-risk myeloma may:

• Return more quickly after treatment
• Respond differently to standard therapies
• Require more effective long-term treatment strategies

Horizon Two was specifically created to help researchers identify better treatment approaches for this patient population.

Who may be able to join?

You may be eligible if you:

• Are 18 years or older
• Have been diagnosed with high-risk multiple myeloma within six months of screening
• Have not yet started treatment or are newly diagnosed
• Meet other study requirements determined by the study team

A study doctor will review your medical history and test results to determine whether the trial may be appropriate for you.

Is there financial support available?

Yes – the MMRF has partnered with Family Reach to offer grants to help cover non-medical expenses, including mortgage/rent payments, utilities, groceries, and transportation. If you have questions, please contact [email protected] or call them at (857) 233-2764.

Questions to Ask Your Doctor

If you are considering this trial, you may want to ask your doctor:

• Is this study appropriate for my type of myeloma?
• What are the possible risks and benefits?
• How might participation affect my current treatment plan?

Am I eligible?

The MMRF Patient Navigation Center (PNC) can help answer any additional questions you have about Horizon Two, and can even pre-screen you to see if you are eligible for Horizon or other clinical trials. Contact the PNC today to learn more.